Recent Quotes (30 days)

You have no recent quotes
chg | %

Merus Labs International Inc (USA)  

(Public, NASDAQ:MSLI)   Watch this stock  
Find more results for MSLI
0.950
-0.050 (-4.99%)
Dec 2 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.95 - 0.99
52 week 0.81 - 1.90
Open 0.96
Vol / Avg. 5,377.00/15,275.00
Mkt cap 104.37M
P/E     -
Div/yield     -
EPS -0.07
Shares 117.00M
Beta 1.69
Inst. own 0%

Key stats and ratios

Q2 (Jun '16) 2015
Net profit margin -19.69% -0.49%
Operating margin -7.22% 12.66%
EBITD margin - 61.48%
Return on average assets -5.35% -0.10%
Return on average equity -10.23% -0.17%
Employees 6 -
CDP Score - -

Address

100 Wellington St. West Suite 2110 Stn Toronto Dom PO Box 151
TORONTO, ON M5K 1H1
Canada
+1-416-5933701 (Phone)
+1-416-5934434 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Merus Labs International Inc. is a specialty pharmaceutical company. The Company is engaged in the acquisition and licensing of branded prescription pharmaceutical products. It acquires, in-licenses, markets and distributes pharmaceutical products in Canada and internationally. Its products include nitrates portfolio, such as Elantan, Isoket and Deponit; Sintrom; Emselex/Enablex; Surgestone and Provames; Speciafoldine; Tredemine; Salagen; Estraderm MX, and Vancocin. It has presence in cardiovascular and women's health markets. It is focusing on prescription products in additional therapeutic areas, such as urology, central nervous system (CNS), oncology support, dermatology, ophthalmology, nephrology and anti-infectives. It owns, markets and distributes pharmaceutical products within various territories. The Company carries out business principally in Canada and Europe. It also sells products in Australia, South Korea and Mexico.

Officers and directors

Michael S. Cloutier Independent Chairman of the Board
Bio & Compensation  - Reuters
Barry Fishman Chief Executive Officer, Director
Bio & Compensation  - Reuters
Michael Bumby Chief Financial Officer
Age: 51
Bio & Compensation  - Reuters
Robert McLay Vice President - Sales and Marketing
Bio & Compensation  - Reuters
Frank Rotmann Vice President and Head of European Operations
Bio & Compensation  - Reuters
Robert Bloch M.D. Director
Bio & Compensation  - Reuters
Theresa Sheila Firestone Independent Director
Bio & Compensation  - Reuters
David D. Guebert CPA Independent Director
Bio & Compensation  - Reuters
Robert S. Pollock Independent Director
Bio & Compensation  - Reuters
Timothy G. Sorensen Independent Director
Bio & Compensation  - Reuters